Where is Viking Therapeutics (VKTX) Headed According to Analysts?

Core Insights - Viking Therapeutics, Inc. (NASDAQ:VKTX) is recognized as a high-potential biotech stock, with analysts maintaining a bullish outlook and setting price targets of $102 and $125 [1][3] - The company's strong market position is attributed to its competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs, which are seen as significant strengths [2] Analyst Ratings - H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating for VKTX on September 22, with a price target of $102 [1] - BTIG analyst Justin Zelin also maintained a Buy rating, setting a higher price target of $125, emphasizing the company's solid position in the metabolic disease and obesity market [3] Company Overview - Viking Therapeutics, Inc. is a clinical-stage company focused on developing therapies for metabolic and endocrine disorders [3]